Original PaperChemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins
Introduction
Prostate cancer is the most common cancer in men and one of the leading causes of cancer death[1]. Metastatic disease is a major oncological problem and is not curable, but palliation can be achieved by hormone deprivation therapy[2]. However, prostate cancer patients will relapse at some stage in time, the majority within 1–2 years after starting endocrine therapy. After failure of hormone therapy, there are no successful treatment strategies available with respect to prolongation of survival and patients will die of progressive, hormone-independent disease after an average period of 40 weeks following relapse[3].
Hormone-independent prostate cancer is resistant to a broad range of antineoplastic agents[4], which may be caused by the fact that large proportions of prostate cancer cells are in interphase[5]. Also, multidrug resistance (MDR), the resistance of cancer cells to a variety of structurally and functionally distinct cytotoxic agents, may play an important role in progressive therapy resistant prostate cancer. However, the role of MDR in prostate cancer remains to be elucidated. A better understanding of mechanisms underlying the resistance of prostate cancer to chemotherapy may lead to novel approaches to challenge hormone unresponsive prostate cancer more successfully.
We determined the expression of eight MDR-associated proteins in prostate cancer cell lines derived from patients with progressive disease: the drug transporter molecules P-glycoprotein (Pgp)[6]and MDR-associated protein (MRP[7], the detoxifying enzyme glutathione-S-transferase-π (GST-π)[8], modulators of apoptosis Bcl-2[9]and Bax[10]and the enzymes topoisomerase (Topo) I, IIα and IIβ, which are related to one form of MDR: atypical or attenuated MDR[11]. Furthermore, we measured the response of the cell lines to treatment with the cytotoxic agents etoposide, doxorubicin and vinblastin, which are commonly used in the treatment of several malignancies and have been used to challenge prostate cancer in clinical trials.
Section snippets
Cell lines and culture conditions
The human prostate cancer cell lines PC3[12], TSU-Pr1[13], DU145[14]and LNCaP sublines that were established from the original LNCaP line[15]: the androgen-dependent FGC (available through the ATCC, Rockville, Maryland, U.S.A.), the hormone unresponsive R line[16]and the hormone-independent LNO line[17], were maintained at 37°C in a 5% CO2–95% air atmosphere. PC3, TSU-Pr1, DU145, LNCaP-R and LNCaP-FGC were cultured in RPMI 1640 medium, supplemented with 7.5% fetal calf serum (FCS), 1 unit/ml
Chemosensitivity assay
Drug-induced inhibition of human prostate cancer cell growth by the anticancer agents etoposide, doxorubicin and vinblastin was established in vitro. The growth of the cell lines during the assay, defined as the optical density (OD) value after 72 h divided by the OD value after plating of the cells, was 5.4, 2.6, 3.3, 1.5, 3.3 and 3 for TSU-Pr1, LNCaP-FGC, PC3, LNCaP-LNO, LNCaP-R and DU145, respectively. This indicates that drug testing was performed under the condition of cell lines in
Discussion
To gain insight into the mechanisms involved in the resistance of metastatic hormone-independent prostate cancer to chemotherapy we determined the expression of MDR proteins, which may lead to the MDR phenotype, in prostate cancer cell lines. Furthermore, we assessed the resistance profiles to three commonly used antineoplastic agents, etoposide, doxorubicin and vinblastin, whose action is affected by MDR.
We found that the expression of Pgp, the energy-dependent drug transporter molecule, was
Acknowledgements
Supported by Research Grant (9606) from the Dutch Research Foundation (SUWO).
References (39)
- et al.
Establishment of a new prostatic carcinoma cell line (TSU-Pr1)
J. Urol.
(1987) - et al.
The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity
J. Steroid. Biochemic. Molec. Biol.
(1991) - et al.
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines
J. Urol.
(1993) - et al.
Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice
J. Urol.
(1993) - et al.
Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells
Biochim. Biophys. Acta
(1995) - et al.
The epidemiology of prostatic cancer. Geographical distribution and time-trends
Acta Oncol.
(1991) - et al.
Hormonal therapy of prostatic cancer
Cancer
(1980) - et al.
Management of relapsing disease in prostate cancer
Cancer
(1992) - et al.
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
Cancer
(1993) - et al.
S-phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling
Cancer
(1990)
Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines
Science
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line (see comments)
Science
Glutathione S-transferases: gene structure, regulation, and biological function
Annu. Rev. Biochem.
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Nature
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
Cell
Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistant human leukemic cells
Cancer Res.
Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
Invest. Urol.
Isolation of a human prostate carcinoma cell line (DU 145)
Int. J. Cancer
LNCaP model of human prostatic carcinoma
Cancer Res.
Cited by (95)
Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer
2017, Journal of Controlled ReleaseMechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
2017, Cancer Treatment ReviewsProtein kinase CK2 is necessary for the adipogenic differentiation of human mesenchymal stem cells
2015, Biochimica et Biophysica Acta - Molecular Cell ResearchCitation Excerpt :Even higher concentrations of CX-4945 (30 and 40 μM) failed to reduce the kinase activity efficiently (data not shown). It is tempting to speculate that hMSC, which share similarities with cancer cells, develop some kind of drug resistance in response to the CX-4945 treatment as it is known for tumour cells [67,69]. Our present data show that CK2 plays a role in the early phase of differentiation.
Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors
2015, International Journal of Biological MacromoleculesMolecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors
2014, Biomedicine and PharmacotherapyCitation Excerpt :The cell permeability properties of the compounds predicted by QuikProp programme of Schrodinger software was not able to account for the above activity difference (Table 1 and Table 4). This observation may be attributed to multi drug resistance-associated proteins MRP or Glutathione-S-transferase (GST) enzyme, which are overexpressed in PC3 cells and are not clients of Hsp90 [49,50]. Further studies are required to validate the proposed hypothesis.